drugset / Trial / NCT00683995

A Phase III Clinical Study of KW-2246

NCT00683995

Phase 3 Completed 43 enrolled Kyowa Kirin, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to assess the safety and efficacy of long-term KW-2246 treatment as rescue medication for breakthrough pain.

Timeline

Start
2008-03
Primary completion
2009-07
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified

Indications

No indication recorded.